Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and PAVmed subsidiary, has scheduled a business update conference call and webcast for March 24, 2025, at 8:30 AM ET.
During the call, Chairman and CEO Lishan Aklog will provide a comprehensive business update, including the company's operations and growth strategy. CFO Dennis McGrath will present the fourth quarter 2024 financial results.
Investors can access the webcast through the company's investor relations website at luciddx.com. For telephone access:
- U.S. callers: 1-800-836-8184
- International callers: 1-646-357-8785
Lucid Diagnostics (Nasdaq: LUCD), un'azienda di diagnostica medica per la prevenzione del cancro in fase commerciale e sussidiaria di PAVmed, ha programmato una conferenza telefonica e un webcast per un aggiornamento aziendale il 24 marzo 2025, alle 8:30 AM ET.
Durante la chiamata, il Presidente e CEO Lishan Aklog fornirà un aggiornamento completo sull'azienda, comprese le operazioni e la strategia di crescita. Il CFO Dennis McGrath presenterà i risultati finanziari del quarto trimestre 2024.
Gli investitori possono accedere al webcast tramite il sito web delle relazioni con gli investitori dell'azienda su luciddx.com. Per l'accesso telefonico:
- Chiamate dagli Stati Uniti: 1-800-836-8184
- Chiamate internazionali: 1-646-357-8785
Lucid Diagnostics (Nasdaq: LUCD), una empresa de diagnóstico médico en etapa comercial para la prevención del cáncer y subsidiaria de PAVmed, ha programado una llamada de conferencia y un webcast para una actualización empresarial el 24 de marzo de 2025, a las 8:30 AM ET.
Durante la llamada, el Presidente y CEO Lishan Aklog proporcionará una actualización empresarial integral, incluyendo las operaciones de la empresa y la estrategia de crecimiento. El CFO Dennis McGrath presentará los resultados financieros del cuarto trimestre de 2024.
Los inversores pueden acceder al webcast a través del sitio web de relaciones con inversores de la empresa en luciddx.com. Para acceso telefónico:
- Llamadas de EE. UU.: 1-800-836-8184
- Llamadas internacionales: 1-646-357-8785
루시드 진단 (Nasdaq: LUCD), 상업 단계의 암 예방 의료 진단 회사이자 PAVmed의 자회사, 는 2025년 3월 24일 오전 8시 30분 ET에 비즈니스 업데이트 컨퍼런스 콜 및 웹캐스트를 예정하고 있습니다.
전화 회의 중에 회장 겸 CEO 리샨 아클로그가 회사의 운영 및 성장 전략을 포함한 포괄적인 비즈니스 업데이트를 제공합니다. CFO 데니스 맥그라스가 2024년 4분기 재무 결과를 발표할 것입니다.
투자자는 luciddx.com의 회사 투자자 관계 웹사이트를 통해 웹캐스트에 접근할 수 있습니다. 전화 접근 방법:
- 미국 전화: 1-800-836-8184
- 국제 전화: 1-646-357-8785
Lucid Diagnostics (Nasdaq: LUCD), une entreprise de diagnostics médicaux en phase commerciale pour la prévention du cancer et filiale de PAVmed, a programmé une conférence téléphonique et un webcast pour une mise à jour commerciale le 24 mars 2025 à 8h30 ET.
Lors de l'appel, le Président et CEO Lishan Aklog fournira une mise à jour commerciale complète, y compris les opérations de l'entreprise et sa stratégie de croissance. Le CFO Dennis McGrath présentera les résultats financiers du quatrième trimestre 2024.
Les investisseurs peuvent accéder au webcast via le site web des relations avec les investisseurs de l'entreprise à luciddx.com. Pour l'accès téléphonique :
- Appels des États-Unis : 1-800-836-8184
- Appels internationaux : 1-646-357-8785
Lucid Diagnostics (Nasdaq: LUCD), ein Unternehmen für medizinische Diagnostik zur Krebsprävention in der kommerziellen Phase und Tochtergesellschaft von PAVmed, hat eine Telefonkonferenz und einen Webcast für ein Geschäftsupdate am 24. März 2025 um 8:30 Uhr ET angesetzt.
Während des Anrufs wird Vorsitzender und CEO Lishan Aklog ein umfassendes Geschäftsupdate geben, einschließlich der Unternehmensoperationen und Wachstumsstrategie. CFO Dennis McGrath wird die finanziellen Ergebnisse des vierten Quartals 2024 präsentieren.
Investoren können über die Investor-Relations-Website des Unternehmens unter luciddx.com auf den Webcast zugreifen. Für den telefonischen Zugang:
- US-Anrufer: 1-800-836-8184
- Internationale Anrufer: 1-646-357-8785
- None.
- None.
Conference Call and Webcast at 8:30 AM Eastern Time
The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone,
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-march-24-2025-302396541.html
SOURCE Lucid Diagnostics
FAQ
When is Lucid Diagnostics (LUCD) Q4 2024 earnings call scheduled?
How can investors access LUCD's March 24 business update call?
What topics will be covered in Lucid Diagnostics' March 2025 business update?
How long will the replay of LUCD's March 24 earnings call be available?
Which executives will present at Lucid Diagnostics' Q4 2024 earnings call?
